PetMeds® Announces Second Quarter Fiscal 2025 Financial Results

GlobeNewswire11-07

DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481795901?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uEcgkpK9pnbBP6dItHA2jw--~B/aD02ODQ7dz00Mzc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/842e855ad1cfc21d8880466d1833e9d7","is_english":true,"pubTime":"2024-11-07 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481795901","market":"us","top_or_hot":-1,"title":"PetMeds® Announces Second Quarter Fiscal 2025 Financial Results","media":"GlobeNewswire","content":"<div>\n<p>DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended...</p>\n\n<a href=\"https://finance.yahoo.com/news/petmeds-announces-second-quarter-fiscal-210500312.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PetMeds® Announces Second Quarter Fiscal 2025 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPetMeds® Announces Second Quarter Fiscal 2025 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/petmeds-announces-second-quarter-fiscal-210500312.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended...</p>\n\n<a href=\"https://finance.yahoo.com/news/petmeds-announces-second-quarter-fiscal-210500312.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PETS","symbol_name":"PetMed Express","start_time":0,"source_url":"https://finance.yahoo.com/news/petmeds-announces-second-quarter-fiscal-210500312.html","article_id":"2481795901","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uEcgkpK9pnbBP6dItHA2jw--~B/aD02ODQ7dz00Mzc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/842e855ad1cfc21d8880466d1833e9d7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481795901","pubTimestamp":1730927100,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"DELRAY BEACH, Fla., Nov. 06, 2024  -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx  today announced its financial results for its second quarter ended September30, 2024.Net income of $2.3 million, or $0.11 per diluted share, compared to net income of $0.7 million, or $0.03 per diluted share, in the prior year period.Adjusted EBITDA of $2.1 million improved sequentially from an Adjusted EBITDA loss of $(1.5) million in the first quarter of fiscal 2025 and compared to Adjusted EBITDA of $3.4 million in the prior year period.To access the replay, call  512-2921  or  317-6671 and enter passcode 13748837.Founded in 1996, PetMeds is a leader in the consumer pet healthcare sector. As a national online retailer with expert pharmacists and licenses across fifty states, PetMeds.com and PetCareRx.com deliver top branded pharmaceuticals, generics, compounded prescription medications and OTC supplements and vitamins that help pets live longer, healthier lives. Leveraging telehea","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PETS":"PetMed Express","BK4122":"互联网与直销零售","BK4200":"专卖店"},"translate_title":"PetMeds®公布2025财年第二季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PETS":0.9},"content_text":"DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2024.\nSecond Quarter Fiscal 2025 Financial Highlights\n\nNet sales of $59.6 million.\nGross margin of 29.1%, an increase of 0.8% compared to the prior year period.\nNet income of $2.3 million, or $0.11 per diluted share, compared to net income of $0.7 million, or $0.03 per diluted share, in the prior year period.  \nAdjusted EBITDA of $2.1 million improved sequentially from an Adjusted EBITDA loss of $(1.5) million in the first quarter of fiscal 2025 and compared to Adjusted EBITDA of $3.4 million in the prior year period.\nContinued progress on key initiatives supporting the transformation of the business.\n\n“We demonstrated significant progress on key initiatives of phase one of our transformation, aimed at improving profitability during the second quarter while also advancing our vision of being a leader in the consumer pet healthcare sector,” said Sandra Campos, CEO & President.   “By consolidating and streamlining our PetMeds and PetCareRX back-of-the-house operations, we’ve materially lowered our cost structure, which helped us deliver a strong sequential improvement in Adjusted EBITDA during the second quarter.   We are now well positioned to lean more aggressively into differentiating product assortments, brand awareness campaigns, and core marketing initiatives to drive growth. While it’s still very early in our turnaround, we remain confident in our direction and belief that the changes and investments we are making across our business will create a more compelling, enduring value proposition for all stakeholders and will significantly strengthen our competitive position.”\nThis afternoon the Company will host a conference call to review the quarter’s financial results.\nTime: 4:30 P.M. Eastern Time, November 6, 2024\nPublic call dial in (877) 407-0789 (toll free) or (201) 689-8562.\nWebcast stream link: https://investors.petmeds.com for those who wish to stream the call via webcast.\nReplay: Available until November 20, 2024, at 11:59 P.M Eastern Time.\nTo access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 13748837.\nAbout PetMed Express, Inc.\nFounded in 1996, PetMeds is a leader in the consumer pet healthcare sector. As a national online retailer with expert pharmacists and licenses across fifty states, PetMeds.com and PetCareRx.com deliver top branded pharmaceuticals, generics, compounded prescription medications and OTC supplements and vitamins that help pets live longer, healthier lives. Leveraging telehealth and insurance partnerships, they offer unparalleled value and convenience that enhance wellness and longevity for dogs, cats, and horses. PetMeds and PetCareRx provides essential pet health offerings through their websites, www.PetMeds.com and www.PetCareRx.com.\nForward Looking Statement\nThis press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan.   Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.\nPETMEDS INVESTOR RELATIONS CONTACTICR, LLCJohn Mills(646) 277-1254\nReed Anderson(646) 277-1260investor@petmeds.com\n\n\n\n \n\n\nPETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except for share and per share data)\n\n\n \n \n \n \n\n\n \nSeptember 30,2024\n \nMarch 31,2024\n\n\n \n(Unaudited)\n \n \n\n\nASSETS\n \n \n \n\n\n \n \n \n \n\n\nCurrent assets:\n \n \n \n\n\nCash and cash equivalents\n$\n52,045\n \n \n$\n55,296\n \n\n\nAccounts receivable, less allowance for credit losses of $27 and $273, respectively\n \n1,620\n \n \n \n3,283\n \n\n\nInventories, net\n \n13,092\n \n \n \n28,556\n \n\n\nPrepaid expenses and other current assets\n \n3,655\n \n \n \n6,325\n \n\n\nPrepaid income taxes\n \n367\n \n \n \n188\n \n\n\nTotal current assets\n \n70,779\n \n \n \n93,648\n \n\n\n \n \n \n \n\n\nNoncurrent assets:\n \n \n \n\n\nProperty and equipment, net\n \n26,204\n \n \n \n26,657\n \n\n\nIntangible and other assets, net\n \n15,524\n \n \n \n16,503\n \n\n\nGoodwill\n \n26,658\n \n \n \n26,658\n \n\n\nOperating lease right-of-use assets\n \n1,188\n \n \n \n1,432\n \n\n\nDeferred tax assets, net\n \n5,681\n \n \n \n4,986\n \n\n\nTotal noncurrent assets\n \n75,255\n \n \n \n76,236\n \n\n\n \n \n \n \n\n\nTotal assets\n$\n146,034\n \n \n$\n169,884\n \n\n\n \n \n \n \n\n\nLIABILITIES AND SHAREHOLDERS' EQUITY\n \n \n \n\n\n \n \n \n \n\n\nCurrent liabilities:\n \n \n \n\n\nAccounts payable\n$\n16,951\n \n \n$\n37,024\n \n\n\nSales tax payable\n \n24,373\n \n \n \n25,012\n \n\n\nAccrued expenses and other current liabilities\n \n5,412\n \n \n \n7,060\n \n\n\nCurrent operating lease liabilities\n \n446\n \n \n \n459\n \n\n\nDeferred revenue\n \n1,650\n \n \n \n2,603\n \n\n\nTotal current liabilities\n \n48,832\n \n \n \n72,158\n \n\n\n \n \n \n \n\n\nOperating lease liabilities, net of current lease liabilities\n \n768\n \n \n \n995\n \n\n\n \n \n \n \n\n\nTotal liabilities\n \n49,600\n \n \n \n73,153\n \n\n\n \n \n \n \n\n\nCommitments and contingencies\n \n \n \n\n\n \n \n \n \n\n\nShareholders' equity:\n \n \n \n\n\nPreferred stock, $.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share\n \n9\n \n \n \n9\n \n\n\nCommon stock, $.001 par value, 40,000,000 shares authorized; 20,663,218 and 21,148,692 shares issued and outstanding, respectively\n \n21\n \n \n \n21\n \n\n\nAdditional paid-in capital\n \n17,515\n \n \n \n25,146\n \n\n\nRetained earnings\n \n78,889\n \n \n \n71,555\n \n\n\n \n \n \n \n\n\nTotal shareholders' equity\n \n96,434\n \n \n \n96,731\n \n\n\n \n \n \n \n\n\nTotal liabilities and shareholders' equity\n$\n146,034\n \n \n$\n169,884\n \n\n\n \n \n \n \n\n\n\n\n\n\n \n\n\nPETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except for share and per share amounts) (Unaudited)\n\n\n \n \n \n \n\n\n \nThree Months EndedSeptember 30,\n \nSix Months EndedSeptember 30,\n\n\n \n2024\n \n2023\n \n2024\n \n2023\n\n\n \n \n \n \n \n \n \n \n\n\nNet sales\n$\n59,570\n \n \n$\n70,999\n \n \n$\n127,522\n \n \n$\n149,243\n \n\n\nCost of sales\n \n42,259\n \n \n \n50,937\n \n \n \n92,240\n \n \n \n106,655\n \n\n\n \n \n \n \n \n \n \n \n\n\nGross profit\n \n17,311\n \n \n \n20,062\n \n \n \n35,282\n \n \n \n42,588\n \n\n\n \n \n \n \n \n \n \n \n\n\nOperating expenses:\n \n \n \n \n \n \n \n\n\nGeneral and administrative\n \n10,493\n \n \n \n11,962\n \n \n \n15,367\n \n \n \n27,673\n \n\n\nAdvertising\n \n4,606\n \n \n \n5,512\n \n \n \n11,596\n \n \n \n12,777\n \n\n\nDepreciation and amortization\n \n1,658\n \n \n \n1,713\n \n \n \n3,379\n \n \n \n3,391\n \n\n\nTotal operating expenses\n \n16,757\n \n \n \n19,187\n \n \n \n30,342\n \n \n \n43,841\n \n\n\n \n \n \n \n \n \n \n \n\n\nIncome (loss) from operations\n \n554\n \n \n \n875\n \n \n \n4,940\n \n \n \n(1,253\n)\n\n\n \n \n \n \n \n \n \n \n\n\nOther income:\n \n \n \n \n \n \n \n\n\nInterest income, net\n \n185\n \n \n \n151\n \n \n \n280\n \n \n \n345\n \n\n\nOther, net\n \n186\n \n \n \n254\n \n \n \n417\n \n \n \n760\n \n\n\nTotal other income\n \n371\n \n \n \n405\n \n \n \n697\n \n \n \n1,105\n \n\n\n \n \n \n \n \n \n \n \n\n\nIncome (loss) before (benefit) provision for income taxes\n \n925\n \n \n \n1,280\n \n \n \n5,637\n \n \n \n(148\n)\n\n\n \n \n \n \n \n \n \n \n\n\n(Benefit) provision for income taxes\n \n(1,401\n)\n \n \n565\n \n \n \n(443\n)\n \n \n273\n \n\n\n \n \n \n \n \n \n \n \n\n\nNet income (loss)\n$\n2,326\n \n \n$\n715\n \n \n$\n6,080\n \n \n$\n(421\n)\n\n\n \n \n \n \n \n \n \n \n\n\nNet income (loss) per common share:\n \n \n \n \n \n \n \n\n\nBasic\n$\n0.11\n \n \n$\n0.04\n \n \n$\n0.30\n \n \n$\n(0.02\n)\n\n\nDiluted\n$\n0.11\n \n \n$\n0.03\n \n \n$\n0.29\n \n \n$\n(0.02\n)\n\n\n \n \n \n \n \n \n \n \n\n\nWeighted average number of common shares outstanding:\n \n \n \n \n \n \n \n\n\nBasic\n \n20,597,807\n \n \n \n20,382,979\n \n \n \n20,555,544\n \n \n \n20,357,752\n \n\n\nDiluted\n \n20,938,817\n \n \n \n20,780,455\n \n \n \n20,940,161\n \n \n \n20,357,752\n \n\n\n \n \n \n \n \n \n \n \n\n\nCash dividends declared per common share\n$\n—\n \n \n$\n0.30\n \n \n$\n—\n \n \n$\n0.60\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n \n\n\nPETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands) (Unaudited)\n\n\n \n \n\n\n \nSix Months EndedSeptember 30,\n\n\n \n2024\n \n2023\n\n\nCash flows from operating activities:\n \n \n \n\n\nNet income (loss)\n$\n6,080\n \n \n$\n(421\n)\n\n\nAdjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:\n \n \n \n\n\nDepreciation and amortization\n \n3,379\n \n \n \n3,391\n \n\n\nShare based compensation\n \n(7,631\n)\n \n \n3,489\n \n\n\nDeferred income taxes\n \n(696\n)\n \n \n(146\n)\n\n\nBad debt expense\n \n176\n \n \n \n36\n \n\n\n(Increase) decrease in operating assets and increase (decrease) in operating liabilities:\n \n \n \n\n\nAccounts receivable\n \n1,488\n \n \n \n(345\n)\n\n\nInventories, net\n \n15,464\n \n \n \n3,237\n \n\n\nPrepaid income taxes\n \n(179\n)\n \n \n426\n \n\n\nPrepaid expenses and other current assets\n \n2,670\n \n \n \n(3,516\n)\n\n\nOperating lease right-of-use assets, net\n \n245\n \n \n \n394\n \n\n\nAccounts payable\n \n(20,071\n)\n \n \n(5,542\n)\n\n\nSales tax payable\n \n(639\n)\n \n \n(1,278\n)\n\n\nAccrued expenses and other current liabilities\n \n(221\n)\n \n \n(136\n)\n\n\nLease liabilities\n \n(240\n)\n \n \n(383\n)\n\n\nDeferred revenue\n \n(953\n)\n \n \n579\n \n\n\nNet cash (used in) provided by operating activities\n$\n(1,128\n)\n \n$\n(215\n)\n\n\n \n \n \n \n\n\nCash flows from investing activities:\n \n \n \n\n\nAcquisition of PetCareRx, net of cash acquired\n \n–\n \n \n \n(35,859\n)\n\n\nPurchases of property and equipment\n \n(1,948\n)\n \n \n(2,137\n)\n\n\nNet cash used in investing activities\n$\n(1,948\n)\n \n$\n(37,996\n)\n\n\n \n \n \n \n\n\nCash flows from financing activities:\n \n \n \n\n\nDividends paid\n \n(175\n)\n \n \n(12,404\n)\n\n\nNet cash used in financing activities\n$\n(175\n)\n \n$\n(12,404\n)\n\n\n \n \n \n \n\n\nNet decrease in cash and cash equivalents\n \n(3,251\n)\n \n \n(50,615\n)\n\n\nCash and cash equivalents, at beginning of period\n \n55,296\n \n \n \n104,086\n \n\n\n \n \n \n \n\n\nCash and cash equivalents, at end of period\n$\n52,045\n \n \n$\n53,471\n \n\n\n \n \n \n \n\n\nSupplemental disclosure of cash flow information:\n \n \n \n\n\n \n \n \n \n\n\nCash paid for income taxes\n$\n466\n \n \n$\n–\n \n\n\n \n \n \n \n\n\nDividends payable in accrued expenses and other current liabilities\n$\n39\n \n \n$\n1,513\n \n\n\n \n \n \n \n \n \n \n \n\n\n\nNon-GAAP Financial Measures\nTo provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.\nWe have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.\nWe believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:\n\nAlthough depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;\nAdjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;\nAdjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;\nAdjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;\nAdjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;\nAdjusted EBITDA does not reflect certain expenses including the estimated state sales tax accrual which reduces cash available to us.\nOther companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.\n\nBecause of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.\nThe following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated:\n\n\n\n \n\n\nReconciliation of Non-GAAP MeasuresPetMed Express, Inc.(Unaudited)\n\n\n \n \n \n \n\n\n \nThree Months Ended\n \nIncrease (Decrease)\n\n\n($ in thousands, except percentages)\nSeptember 30,2024\n \nSeptember 30,2023\n \n$\n \n%\n\n\n \n \n \n \n \n \n \n \n\n\nConsolidated Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA:\n\n\n \n \n \n \n \n \n \n \n\n\nNet income\n$\n2,326\n \n \n$\n715\n \n \n$\n1,611\n \n \n225\n%\n\n\n \n \n \n \n \n \n \n \n\n\nAdd (subtract):\n \n \n \n \n \n \n \n\n\nStock-based Compensation\n$\n573\n \n \n$\n1,728\n \n \n$\n(1,155\n)\n \n(67\n)%\n\n\nIncome Taxes\n$\n(1,401\n)\n \n$\n565\n \n \n$\n(1,966\n)\n \n(348\n)%\n\n\nDepreciation and Amortization\n$\n1,658\n \n \n$\n1,713\n \n \n$\n(55\n)\n \n(3\n)%\n\n\nInterest (Income), Net(1)\n$\n(185\n)\n \n$\n(151\n)\n \n$\n(34\n)\n \n23\n%\n\n\nAcquisition/Partnership Transactions and Other Items\n$\n–\n \n \n$\n168\n \n \n$\n(168\n)\n \n(100\n)%\n\n\nEmployee Severance\n$\n305\n \n \n$\n15\n \n \n$\n290\n \n \n1933\n%\n\n\nSales Tax (Income)\n$\n(1,178\n)\n \n$\n(1,316\n)\n \n$\n138\n \n \n(10\n)%\n\n\n \n \n \n \n \n \n \n \n\n\nAdjusted EBITDA\n$\n2,098\n \n \n$\n3,437\n \n \n$\n(1,339\n)\n \n(39\n)%\n\n\n\n(1) Included in interest income, net is $0.4 million of interest expense related to the sales tax liability and $0.6 million of interest income for the three months ended September 30, 2024. This compares to $0.4 million of interest expense related to the sales tax liability and $0.6 million of interest income for the three months ended September 30, 2023.\n\n\n\n \n \n \n \n\n\n \nSix Months Ended\n \nIncrease (Decrease)\n\n\n($ in thousands, except percentages)\nSeptember 30,2024\n \nSeptember 30,2023\n \n$\n \n%\n\n\n \n \n \n \n \n \n \n \n\n\nConsolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:\n\n\n \n \n \n \n \n \n \n \n\n\nNet income\n$\n6,080\n \n \n$\n(421\n)\n \n$\n6,501\n \n \n(1544\n)%\n\n\n \n \n \n \n \n \n \n \n\n\nAdd (subtract):\n \n \n \n \n \n \n \n\n\nStock-based Compensation\n$\n(7,631\n)\n \n$\n3,488\n \n \n$\n(11,119\n)\n \n(319\n)%\n\n\nIncome Taxes\n$\n(443\n)\n \n$\n273\n \n \n$\n(716\n)\n \n(262\n)%\n\n\nDepreciation and Amortization\n$\n3,379\n \n \n$\n3,391\n \n \n$\n(12\n)\n \n—\n%\n\n\nInterest (Income), Net (1)\n$\n(280\n)\n \n$\n(345\n)\n \n$\n65\n \n \n(19\n)%\n\n\nAcquisition/Partnership Transactions and Other Items\n$\n180\n \n \n$\n1,294\n \n \n$\n(1,114\n)\n \n(86\n)%\n\n\nEmployee Severance\n$\n454\n \n \n$\n408\n \n \n$\n46\n \n \n11\n%\n\n\nSales Tax (Income)\n$\n(1,178\n)\n \n$\n(1,316\n)\n \n$\n138\n \n \n(10\n)%\n\n\n \n \n \n \n \n \n \n \n\n\nAdjusted EBITDA\n$\n561\n \n \n$\n6,772\n \n \n$\n(6,211\n)\n \n(92\n)%\n\n\n\n(1) Included in interest income, net is $0.8 million of interest expense related to the sales tax liability and $1.1 million of interest income for the six months ended September 30, 2024. This compares to $0.8 million of interest expense related to the sales tax liability and $1.2 million of interest income for the six months ended September 30, 2023.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481795901"}